<DOC>
	<DOCNO>NCT02028767</DOCNO>
	<brief_summary>The trial conduct establish bioequivalence emp/met ( 12.5mg/500mg ) fix dose combination tablet compare tablet administer together healthy male female volunteer feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Healthy Volunteers Empagliflozin/Metformin Fixed Dose Combination Compared Separate Tablets</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord investigator 's assessment , base follow criterion : complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG clinical laboratory test . 2 . Age 18 50 year ( inclusive ) 3 . BMI 18.5 29.9 kg/m2 ( inclusive ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Any finding medical examination ( Including blood pressure [ BP ] , pulse rate [ PR ] , electrocardiogram [ ECG ] ) deviate normal judge clinically relevant investigator . 2 . Any evidence concomitant disease judge clinically relevant investigator . 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . 4 . Surgery gastrointestinal tract could interfere kinetics study drug ( ) 5 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder . 6 . History relevant orthostatic hypotension , faint spell , blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy trial medication 's excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within 30 day less 10 halflives respective drug prior administration trial medication . 10 . Within 14 day prior administration trial medication , use drug might reasonably influence result trial , base current knowledge 11 . Participation another trial investigational drug administration within 60 day prior administration trial medication . 12 . Smoker ( use tobacco nicotinecontaining product within 6 month prior administration trial medication ) 13 . Inability refrain smoke specify trial day 14 . Alcohol abuse ( consumption 20g/day female 30g/day male &gt; 7 alcoholcontaining drink per week ) 15 . Drug abuse positive drug screen 16 . Blood donation ( 100 ml wihtin 30 day prior administration trial medication intend trial ) 17 . Intention perform excessive physical activity within one week prior administration trial medication trial 18 . Inability comply dietary regimen trial site 19 . Subject assessed investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study . For female subject : 20 . Positive pregnancy test , pregnancy plan become pregnant within 30 day study completion . 21 . No adequate contraception study 1 month study completion , i.e . follow : implant , injectables , combine oral contraceptive , IUD ( intrauterine device ) , sexual abstinence least 1 month prior enrolment , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females , vasectomise partner , sexually abstinent , surgically sterile , post menopausal ask use additional barrier method ( e.g . condom , diaphragm spermicide ) . Postmenopausal define least 1 year spontaneous amenorrhea deem post menopausal physician base screen clinical laboratory test ( follicle stimulate hormone luteinizing hormone ) . 22 . Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>